|
|
|
| home > epc > winter 2001 > the trojan horse of oncology - the role of stealth drug delivery |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
The word 'cancer' instils fear into most people. One in four people will develop cancer at some point in their life and, given the dismal cure rates for most common cancers, many of those who are diagnosed with some form of the disease will eventually die of it. Fear is often augmented by the knowledge that the relentlessly growing cancer often brings with it pain, suffering and debility.
Far from being 'mindless' automatons, it has been shown that tumour cells employ numerous strategies to promote growth. Complicated mechanisms to switch on growth; vascular endothelial growth factors (VEGF) to create a blood supply as a pipeline to bring nutrients; and pumps such as p-Glycoprotein to get rid of ingested cellular toxins are some of the strategies that have evolved.
While the fight against cancer begins with prevention, once it has developed, permanent eradication of the disease requires all the skills oncologists can muster to outwit the tumour cell and the mechanisms it employs to ensure its continued cellular survival and tumour growth.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Cambridge Healthtech Institute Third Annual SCOPE Summit
7-9 February 2012, Miami Hilton Downtown, Miami FL
The program brings together six conferences under the SCOPE umbrella, which creates an opportunity for idea sharing and cross pollination amongst clinical operations professionals from different groups. Despite a shared exhibit floor where the community can share ideas, each conference remains autonomous and goes deeply into its own set of issues with its expert faculty. Each conference will feature best practice case studies and interactive discussions relevant to clinical operations experts as well as those new to the field.
More info >> |
|
 |
News and Press Releases |
 |
APTAR PHARMA’S PRESERVATIVE-FREE MULTIDOSE DISPENSER OSD CHOSEN FOR THE FIRST TIME FOR AN EYE CARE PRODUCT
Aptar Pharma’s innovative and patented preservative-free multidose Ophthalmic Squeeze Dispenser (OSD) has found its first application for the treatment of dry eye with the launch of VISMED® MULTI. Aptar Pharma has worked closely with the Swiss-German based Eye Care specialist TRB Chemedica for improving patient safety, achieving dosing accuracy and maintaining product stability on the ophthalmic spray device.
More info >> |
|
|
